The FDA has decided to reconsider removing Eli Lilly’s tirzepatide from its shortage list and will not pursue regulatory action against compounding pharmacies making copies of the drug. This decision came after many objected to the FDA’s previous announcement that the shortage of the drug had ended and compounding pharmacies would no longer be allowed to manufacture it. A group representing compounding pharmacies filed a lawsuit against the FDA, claiming the drug was still in short supply. The FDA’s decision to reconsider comes after backlash from compounders, telehealth companies, and patients.
Source link
FDA to reconsider removal of Eli Lilly weight loss drug from shortage list
